Sign In
Cook Children's
Patient Portal

Histiocytic Disorders Program

Consultations and referrals

phone icon
Call 682-885-4007

Histiocytosis is a broad description for a rare group of disorders driven by abnormal increase in the number of histiocytes, a type of white blood cell. The two important types of histiocytoses are: Langerhans cell histiocytosis (LCH) and Hemophagocytic lymphohistiocytosis (HLH). While these disorders are rare, Cook Children’s has created a team of doctors, nurses, research analysts, and pharmacists who are dedicated to the care of your child.

Our Histiocytic Disorders team is experienced in treating a wide range of histocytic disorders like LCH and HLH. In addition to being proud members of the Histocytic Society, we offer the most comprehensive and highest level of care in North Texas. Due to the expertise of our team in this area, we serve as a referral center for patients both inside and outside our region.

Why Cook Children's

Our expertise and collaborations with ongoing clinical trials and innovative approaches rely on a team of specialists form Hematology and Oncology, as well as Interventional Radiology, Orthopedics, Radiology, Endocrinology, and Neurosurgery.

Our multidisciplinary clinical team remains committed to providing the highest level of care for this rare group of disorders. We meet weekly to review our newly diagnosed patients and create individualized treatment plans and review clinical trial options. To support our patient's psychosocial needs we partner with our Adolescent Young Adult (AYA) and Integrated Oncology teams. We also meet monthly to review our patients, their treatment plans, and clinical trial options, where we join forces with leading Children's hospitals and specialists nationwide. We collaborate with Texas Children's Hospital to offer the benefit of participating in studies. Currently open to enrollment is the LCH Reason Study, which compares previously used vinblastine/prednisone to a single therapy option with cytarabine.

It is possible that some patients may face a sustained relapse. If this occurs, we rely on gene testing to identify patients with genetic changes, such as BRAF, which may be treated with a non-chemotherapeutic approach. Our team partners with Foundation One Medicine to perform detailed genomic testing which identifies specific components of your child's disorder that can be targeted by individual medications. Most importantly, we partner with parents and caregivers to offer family centered care and meet your family's specific needs, while remaining dedicated to offering exceptional care to your child and your family.

Our Team

Anish Ray, M.D., Cook Children's Hematology and Oncology Center, director of the LCH program, has developed a comprehensive approach to caring for a patient suspected to have LCH. Cook Children's is committed to caring for all patients suspected of having this condition.

APRN, CPNP-PC/AC – Pediatric Nurse Practitioner Maranda Diaz
APRN, CPNP-PC/AC – Pediatric Nurse Practitioner
Christa Teller MSN, RN, OCN, CPHON – Solid Tumor Program CoordinatorChrista Teller
MSN, RN, OCN, CPHON – Solid Tumor Program Coordinator
Allie Barnes BSN, RN, CPN, CPHON – Pediatric Oncology CoordinatorAllie Barnes
BSN, RN, CPN, CPHON – Pediatric Oncology Coordinator

Team Publications


Langerhans cell histiocytosis (LCH)

What is LCH?

What drives LCH?

What are the signs and symptoms?

Testing and diagnosis?

How is it treated?

What is the long term outlook?

Hemophagocytic lymphohistiocytosis (HLH)

What is HLH?

What causes HLH?

What are the signs and symptoms?

Testing and diagnosis?

How is it treated?

What is the long term outlook?

We are here to help.

Have questions or need to make a referral? We can help. If you would like to speak to one of our staff, please call our offices at 682-885-4007.